Bi D - Search Results

1

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women.

Kim SC, Song YS, Kim YT, Kim YT, Ryu KS, Gunapalaiah B, Bi D, Bock HL, Park JS. Kim SC, et al. Among authors: bi d. J Gynecol Oncol. 2011 Jun 30;22(2):67-75. doi: 10.3802/jgo.2011.22.2.67. J Gynecol Oncol. 2011. PMID: 21860731 Free PMC article.

2

Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years.

Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, Nam JH, Ahn WS, Choi HS, Ng T, Bi D, OK JJ, Descamps D, Bock HL. Kim YJ, et al. Among authors: bi d. J Korean Med Sci. 2010 Aug;25(8):1197-204. doi: 10.3346/jkms.2010.25.8.1197. Epub 2010 Jul 21. J Korean Med Sci. 2010. PMID: 20676333 Free PMC article. Clinical Trial.

3

Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong.

Ngan HY, Cheung AN, Tam KF, Chan KK, Tang HW, Bi D, Descamps D, Bock HL. Ngan HY, et al. Among authors: bi d. Hong Kong Med J. 2010 Jun;16(3):171-9. Hong Kong Med J. 2010. PMID: 20519752 Free article. Clinical Trial.

4

Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Cervical Cancer Vaccine in Malaysian Women Aged 18-35 years: A Randomized Controlled Trial.

Lim BK, Ng KY, Omar J, Omar SZ, Gunapalaiah B, Teoh YL, Bock HL, Bi D. Lim BK, et al. Among authors: bi d. Med J Malaysia. 2014 Feb;69(1):2-8. Med J Malaysia. 2014. PMID: 24814620 Free article.

5

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.

Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, Descamps DJ, Bock HL; Indian HPV Vaccine Study Group. Bhatla N, et al. Among authors: bi d. J Obstet Gynaecol Res. 2010 Feb;36(1):123-32. doi: 10.1111/j.1447-0756.2009.01167.x. J Obstet Gynaecol Res. 2010. PMID: 20178538 Clinical Trial.

6

Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.

Kim CJ, Song R, Chen J, Tavares Da Silva F, Gopala KB, Kim JH, Bi D, Park JS. Kim CJ, et al. Among authors: bi d. Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):837-842. doi: 10.1002/pds.4175. Epub 2017 Mar 7. Pharmacoepidemiol Drug Saf. 2017. PMID: 28266092 Free PMC article.

7

Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial.

Salamanca de la Cueva I, Pahud B, Huang LM, Leonardi M, Garcia-Sicilia J, Céspedes J, Abdelnour A, Tamura T, Kuroki H, Chiu NC, Virta M, Kokko S, Horn M, Panzer F, Kim JH, Jin L, Moerman L, Debacq C, Parra J, Ugarte A, Bi D; Rota-081 Study Group. Salamanca de la Cueva I, et al. Among authors: bi d. J Infect Dis. 2020 May 4;225(12):2106-15. doi: 10.1093/infdis/jiaa210. Online ahead of print. J Infect Dis. 2020. PMID: 32365189 Free PMC article.

8

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.

Zhu FC, Li CG, Pan HX, Zhang YJ, Bi D, Tang HW, Datta S. Zhu FC, et al. Among authors: bi d. Chin J Cancer. 2011 Aug;30(8):559-64. doi: 10.5732/cjc.010.10564. Chin J Cancer. 2011. PMID: 21801604 Free PMC article. Clinical Trial.

9

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.

Tota JE, Struyf F, Merikukka M, Gonzalez P, Kreimer AR, Bi D, Castellsagué X, de Carvalho NS, Garland SM, Harper DM, Karkada N, Peters K, Pope WAJ, Porras C, Quint W, Rodriguez AC, Schiffman M, Schussler J, Skinner SR, Teixeira JC, Wheeler CM, Herrero R, Hildesheim A, Lehtinen M; Costa Rica Vaccine Trial and the PATRICIA study groups. Tota JE, et al. Among authors: bi d. J Natl Cancer Inst. 2017 Jan 28;109(7):djw300. doi: 10.1093/jnci/djw300. Print 2017 Jan. J Natl Cancer Inst. 2017. PMID: 28132019 Free PMC article. Clinical Trial.

10

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.

Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, Wang J, Yang J, Xia G, Dai Q, Tang H, Suryakiran P, Datta SK, Descamps D, Bi D, Struyf F. Zhu F, et al. Among authors: bi d. Hum Vaccin Immunother. 2014;10(7):1795-806. doi: 10.4161/hv.28702. Hum Vaccin Immunother. 2014. PMID: 25424785 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

745 results

Search Page

Filters